ObjectiveGI is delivering provider partners and their patients participating in research a new, all-inclusive platform of clinical research data management.
“Our distributed technology further strengthens ObjectiveGI’s relationships with partner physicians by delivering more information and analytics within the framework of their existing patient care workflows,” says Colleen Hoke, CEO. “This ‘frictionless’ information-sharing approach supports mobile engagement for investigators, improving workflow integration and timely access to clinical research data.”
“This collaboration extends our data-driven solutions platform while maintaining our stringent security and data privacy requirements. The Clinical Research IO product infrastructure adheres to a stringent cloud-readiness process with security reviews, penetration testing and redundancy,” says Gerry Andrady, CTO. The new ObjectiveGI platform incorporates a clinical research–based eSource model that accepts multiple data formats and securely transforms those data sets into more comprehensive reporting and analytics. The result is usable information that can be readily reviewed and utilized within trial management.
ObjectiveGI is engaging next generation research systems to leverage resources and accelerate high-quality data collection, thus allowing for more efficient research execution throughout the patient care continuum.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.